ACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aurora Cannabis Inc. (ACB) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite some positive developments in international markets and product innovation, the company's financial performance shows significant net income and EPS declines. Technical indicators suggest a bearish trend, and there are no strong proprietary trading signals or significant catalysts to justify immediate action.
The technical indicators for ACB are bearish. The MACD histogram is negative and contracting, RSI is neutral at 26.868, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 3.36, with resistance levels at 4.055 and 4.27.
Aurora Cannabis is expanding its product offerings in Australia and New Zealand, focusing on high-margin international markets. The company reported a 7% YoY increase in net revenue for Q3 2026, driven by strong growth in medical cannabis sales. Gross margins improved significantly, up 69.91% YoY.
Net income and EPS have dropped sharply, down -93.63% and -94.23% YoY, respectively. The company is exiting select Canadian consumer cannabis markets, which could limit domestic growth. Technical indicators and market sentiment are bearish, and there are no significant hedge fund or insider trading trends.
In Q3 2026, Aurora Cannabis reported revenue growth of 6.79% YoY to $94.2 million. However, net income dropped significantly by -93.63% YoY to $1.82 million, and EPS fell by -94.23% YoY to $0.03. Gross margins improved to 5.93%, up 69.91% YoY.
Canaccord recently lowered its price target on ACB to C$9 from C$10 while maintaining a Buy rating. Analysts highlight Aurora's leadership in medical cannabis in Canada and its strong position in international markets like Germany, Poland, Australia, and the UK. However, the price target reduction reflects cautious optimism.
